JeanPaul Clozel - Actelion CEO
CEO
Dr. JeanPaul Clozel serves as Chief Executive Officer, Member of the Executive Committee and Delegate of the Board of Directors of Actelion Ltd. At the end of 1997, he cofounded the Company. Mr. Clozel was a practicing cardiologist from 1974 till 1985. He served as Head of Drug Discovery Group in Cardiovascular Department of F. HoffmannLa Roche from 1985 to 1997, where he was responsible for the selection of Tchannel blocker. He also participated in the characterization of renin inhibitors, as well as several endothelin receptor antagonists such as bosentan and clazosentan. He has developed various, novel experimental models allowing the differentiation of these drugs. This work was honored with the 1997 HoffmannLa Roche Research Prize. In 2007, he was nominated professor at the College de France in Paris and as Chair of Technical Innovation. He obtained a medical degree in France and has further training in pharmacology and psychology at the University of Montreal and the University of California.
| Age | 61 |
| Phone | 41 61 565 65 65 |
| Web | http://www.actelion.com |
Actelion Management Efficiency
The company has return on total asset (ROA) of 23.87 % which means that it generated a profit of $23.87 on every $100 spent on assets. This is very large. Similarly, it shows a return on equity (ROE) of 47.08 %, meaning that it generated $47.08 on every $100 dollars invested by stockholders. Actelion's management efficiency ratios could be used to measure how well Actelion manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | CEO Age | ||
| Irit Tobias | Delek Drilling | 45 | |
| Charles Prober | NETGEAR | 53 | |
| Michael Baur | ScanSource | 67 | |
| Yosef Abu | Delek Drilling | 40 | |
| Michael McNamara | Flex | 59 | |
Management Performance
| Return On Equity | 47.08 | |||
| Return On Asset | 23.87 |
Actelion Leadership Team
Elected by the shareholders, the Actelion's board of directors comprises two types of representatives: Actelion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actelion. The board's role is to monitor Actelion's management team and ensure that shareholders' interests are well served. Actelion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actelion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Widman, Co-Founder | ||
| Christian Albrich, Member of the Management Board, Senior Vice President Head Global Human Resources | ||
| Walter Fischli, Senior Vice President Academia Relations | ||
| Robert Bertolini, Member of the Board of Directors | ||
| Carl Feldbaum, Member of the Board of Directors | ||
| Andre Muller, Member of the Management Board, CFO, Executive Vice President | ||
| John Greisch, Director | ||
| Rudi Frank, Senior Vice President Head Global Quality Management, Member of the Extended Executive Committee | ||
| Marian Borovsky, Sr. VP, Group General Counsel and Corporate Secretary | ||
| Werner Henrich, Member of the Board of Directors | ||
| Nicholas Franco, Member of the Management Board, Executive Vice President Chief Business Development Officer | ||
| Martine Clozel, Founder, Chief Scientific Officer, Head of Drug Discovery Pharmacology and Preclinical Devel. and Sr. VP | ||
| Juhani Anttila, Member of the Board of Directors | ||
| JeanPierre Garnier, Chairman of the Board of Directors | ||
| David Stout, Member of the Board of Directors | ||
| JeanPaul Clozel, CEO, Member of the Executive Committee, Delegate to the Board of Directors | ||
| Guy Braunstein, Member of the Management Board, Executive Vice President Head of Clinical Development | ||
| Andrew Weiss, Head of Investor Relations and Corporate Communications and Sr. VP | ||
| Herna Verhagen, Member of the Board of Directors | ||
| Michael Jacobi, Member of the Board of Directors | ||
| Jean Malo, Member of the Board of Directors | ||
| Otto Schwarz, COO and Executive VP | ||
| Roland Haefeli, Member of the Management Board, Senior Vice President Head of Investor Relations & Public Affairs | ||
| Thomas Weller, Vice President Co-Head of Drug Discovery | ||
| Peter Gruss, Member of the Board of Directors |
Actelion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Actelion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 47.08 | |||
| Return On Asset | 23.87 | |||
| Profit Margin | 28.89 % | |||
| Operating Margin | 33.62 % | |||
| Current Valuation | 28.38 B | |||
| Price To Earning | 41.71 X | |||
| Price To Book | 18.07 X | |||
| Price To Sales | 11.91 X | |||
| Revenue | 2.47 B | |||
| Gross Profit | 1.64 B |
Pair Trading with Actelion
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actelion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actelion will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Actelion OTC Stock
If you are still planning to invest in Actelion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Actelion's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |